Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)

TipRanksJul 12 04:17 ET

SpringWorks (SWTX) Completes NDA Submission for Mirdametinib

SpringWorks Therapeutics, Inc. (SWTX Quick QuoteSWTX - Free Report) announced that it has completed the submission of a new drug application (“NDA”) for its investigational MEK inhibitor, mirdametinib, being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients.

Zacks Jul 2 11:30 ET

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)

TipRanksJul 2 07:01 ET

Barclays Issues a Buy Rating on Springworks Therapeutics (SWTX)

TipRanksJul 2 07:00 ET

Sector Update: Health Care Stocks Mixed Premarket Monday

Health care stocks were mixed premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was 0.3% higher and the iShares Biotechnology ETF (IBB) was down 0.2% recently. SpringWorks Therapeutics

MT NewswiresJul 1 09:13 ET

Sector Update: Health Care

Health care stocks were flat to higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was inactive and the iShares Biotechnology ETF (IBB) was up 0.4% recently. SpringWorks Therapeu

MT NewswiresJul 1 08:52 ET